Alzheimer's Association International Conference® (AAIC®) 2024
July 28 - 1, 2024
Description
Move dementia research forward.
Registration is now open for the Alzheimer's Association International Conference® 2024 (AAIC®), July 28-Aug.1, 2024, in Philadelphia, USA, and online.
AAIC is the largest international meeting dedicated to advancing dementia science. Each year, the conference convenes researchers, clinicians and dementia professionals from all career stages to share breaking research discoveries that will lead to improvements in diagnosis, risk reduction and treatments for Alzheimer's disease and other dementia.
Save on registration through May 19 with early bird rates.
Benefit from an ISTAART membership.
The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) is an inclusive global network of more than 10,000 researchers, clinicians and dementia professionals in over 120 countries. Members receive exclusive benefits at AAIC, including discounted in-person and free online registration, invitations to networking events like the ISTAART Reception, and access to Professional Interest Area (PIA) activities.
Look forward to AAIC 2024 plenaries.
AAIC plenary sessions address the field's most crucial and compelling topics. Explore a diverse range of scientific topics through our AAIC 2024 plenaries.
- Bilingualism And Dementia: Implications For Brain Health And Policy
Suvarna Alladi, National Institute of Mental Health and Neurosciences, USA - Dementia Research In Low- And Middle-Income Countries (LMICs): Initiatives That Seize Opportunities, Overcome Challenges and Build Capacity
Ricardo Allegri, Fleni, Argentina - Psychosis In AD
Clive Ballard, King's College London, College of Medicine and Health, University of Exeter, United Kingdom - From Longevity To Vulnerability: Genomic Pathways Underlying Cognitive Health In Centenarians And Neurodegenerative Disease
Henne Holstege, Amsterdam UMC, Netherlands - Neuropathology In A Multidisciplinary Age
Edward Lee, University of Pennsylvania, USA - Antisense Oligonucleotide Therapeutics For Neurodegenerative Diseases
Timothy Miller, Washington University School of Medicine in St. Louis, USA - Preclinical AD
Reisa Sperling, Harvard Medical School, USA - ADNI: Two Decades Of Impact And The Path Forward
Michael Weiner, University of California, San Francisco, Northern California Institute for Research & Education, San Francisco Veterans Administration Medical Center, USA
Contact Info
